AM3102 is an endogenous agonist for proliferator-activated receptor α (PPARα). The biological effects of OEA are terminated by N-acylethanolamine-hydrolyzing acid amidase and fatty-acid amide hydrolase. AM3102 is an OEA analog that stimulates PPARα transcriptional activity with an EC50 value of 100 nM. It is resistant to enzymatic hydrolysis and enhances transcriptional activity of PPARα. AM3102 demonstrates weak affinity for the peripheral cannabinoid (CB2) and central cannabinoid (CB1) receptors with Ki values of 26 and 33 µM, respectively.
1 Astarita, G., et al. 2006. J Pharmacol Exp Ther. 318: 563-570. PMID: 16702440
2 Wang, J. and Ueda, N. 2008. Curr Opin Nephrol Hypertens. 17: 1-10. PMID: 18090663
3 Lin, S., et al. 1998. J Med Chem .41: 5353-5361. PMID: 9876105
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2020 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.